• Imunon announced new Phase 2 OVATION 2 data supporting IMNN-001’s survival benefit in newly diagnosed advanced ovarian cancer.
• Patient biopsies showed stronger anti-tumor immune activity with IMNN-001 plus chemotherapy, providing a biological explanation for improved survival versus chemotherapy alone.
• The findings will be presented at the Society for Immunotherapy of Cancer meeting in Phoenix on November 7, 2026.
• The pivotal Phase 3 OVATION 3 trial is enrolling patients to confirm IMNN-001’s safety and survival benefit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060900PRIMZONEFULLFEED9872067) on November 06, 2026, and is solely responsible for the information contained therein.